Search

Your search keyword '"Othus M"' showing total 312 results
Start Over Author "Othus M"
312 results on '"Othus M"'

1. P1.27-04 Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung

Author

Chae, Y.K., primary, Othus, M., additional, Patel, S.P., additional, Gerber, D.E., additional, Tanvetyanon, T., additional, Chung, L.I.-Y., additional, Kim, H.S., additional, McLeod, C.M., additional, Chen, H.X., additional, Sharon, E., additional, Streicher, H., additional, Ryan, C.W., additional, Blanke, C.D., additional, and Kurzrock, R., additional

Published
2023
Full Text
View/download PDF

4. LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)

Author

Patel, S., primary, Othus, M., additional, Prieto, V., additional, Lowe, M., additional, Buchbinder, E., additional, Chen, Y., additional, Hyngstrom, J., additional, Lao, C.D., additional, Truong, T-G., additional, Chandra, S., additional, Kendra, K., additional, Devoe, C., additional, Hedge, A., additional, Mangla, A., additional, Sharon, E., additional, Korde, L., additional, Moon, J., additional, Sondak, V., additional, and Ribas, A., additional

Published
2022
Full Text
View/download PDF

8. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

Author

Patel, S. P., Othus, M., Chen, Y., Wright Jr., G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., Eisenstein, J. L., Chandra, S., Sosman, J. A., Kendra, K. L., Wu, R. C., Devoe, C. E., Deutsch, G. B., Hegde, A., Khalil, M., and Mangla, A.

Subjects
*POISONS, *ADVERSE health care events, *MELANOMA, *NEOADJUVANT chemotherapy, *PEMBROLIZUMAB, *SURGICAL excision
Abstract

Background: Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown. Methods: In a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) or to surgery followed by pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses) for approximately 1 year or until disease recurred or unacceptable toxic effects developed (adjuvant-only group). The primary end point was event-free survival in the intention-to-treat population. Events were defined as disease progression or toxic effects that precluded surgery; the inability to resect all gross disease; disease progression, surgical complications, or toxic effects of treatment that precluded the initiation of adjuvant therapy within 84 days after surgery; recurrence of melanoma after surgery; or death from any cause. Safety was also evaluated. Results: At a median follow-up of 14.7 months, the neoadjuvant-adjuvant group (154 patients) had significantly longer event-free survival than the adjuvant-only group (159 patients) (P = 0.004 by the log-rank test). In a landmark analysis, event-free survival at 2 years was 72% (95% confidence interval [CI], 64 to 80) in the neoadjuvant-adjuvant group and 49% (95% CI, 41 to 59) in the adjuvant-only group. The percentage of patients with treatment-related adverse events of grades 3 or higher during therapy was 12% in the neoadjuvant-adjuvant group and 14% in the adjuvant-only group. Conclusions: Among patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received pembrolizumab both before and after surgery than among those who received adjuvant pembrolizumab alone. No new toxic effects were identified. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. 1069P Granulomatous and sarcoid-like immune adverse events following CTLA4 and PD1 blockade adjuvant therapy of high-risk melanoma: A combined analysis of ECOG-ACRIN E1609 and SWOG S1404 phase III trials

Author

Noor, A., primary, Yassine, I., additional, Lee, S.J., additional, Othus, M., additional, Moon, J., additional, Kirkwood, J.M., additional, Sondak, V., additional, Ribas, A., additional, Grossmann, K.F., additional, and Tarhini, A.A., additional

Published
2021
Full Text
View/download PDF

24. PF253 SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS

Author

Howard, N.P., primary, Halpern, A.B., additional, Othus, M., additional, Hendrie, P.C., additional, Baclig, N.V., additional, Buckley, S.A., additional, Percival, M.-E.M., additional, Becker, P.S., additional, Scott, B.L., additional, Oehler, V.G., additional, Gernsheimer, T.B., additional, Keel, S.B., additional, Orozco, J.J., additional, Cassaday, R.D., additional, Hartley, G.A., additional, Welch, V., additional, Estey, E.H., additional, and Walter, R.B., additional

Published
2019
Full Text
View/download PDF

26. Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG

Author

Walter RB Othus M Löwenberg B Ossenkoppele GJ Petersdorf SH Pabst T Vekemans MC Appelbaum FR

Abstract

Despite incremental progress over the last several decades adult acute myeloid leukemia (AML) remains difficult to treat and many patients experience therapeutic resistance i.e. never attain a complete remission (CR) despite living long enough to have done so (i.e. are “primary refractory”) or have their disease relapse after achievement of CR.12 It is well recognized that the likelihood of response to therapy for relapsed/refractory AML and subsequent survival varies greatly across individual patients with CR rates of 0–70 and 5 year survival rates of 5–45. Considerable attention has therefore been paid to the assessment of covariates influencing response to salvage therapy in relapsed/refractory AML. The duration of the first CR was identified as primary predictor but cytogenetics at diagnosis age receipt of allogeneic hematopoietic cell transplantation during first CR and number of prior therapies also play a role.3–

Published
2015

29. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

Author

Walter, R.B. (Roland B.), Othus, M. (Megan), Burnett, A.K. (Alan), Löwenberg, B. (Bob), Kantarjian, H. (Hagop), Ossenkoppele, G.J. (Gert), Hills, R.K. (Robert), Ravandi, F. (F.), Pabst, T. (Thomas), Evans, A. (A.), Pierce, S.R. (S. R.), Vekemans, M.-C. (M. C.), Appelbaum, F.R. (Frederick), Estey, E.H. (Elihu), Walter, R.B. (Roland B.), Othus, M. (Megan), Burnett, A.K. (Alan), Löwenberg, B. (Bob), Kantarjian, H. (Hagop), Ossenkoppele, G.J. (Gert), Hills, R.K. (Robert), Ravandi, F. (F.), Pabst, T. (Thomas), Evans, A. (A.), Pierce, S.R. (S. R.), Vekemans, M.-C. (M. C.), Appelbaum, F.R. (Frederick), and Estey, E.H. (Elihu)

Abstract

Therapeutic resistance remains the principal problem in acute myeloid leukemia (AML). We used area under receiver-operating characteristic curves (AUCs) to quantify our ability to predict therapeutic resistance in individual patients, where AUC=1.0 denotes perfect prediction and AUC=0.5 denotes a coin flip, using data from 4601 patients with newly diagnosed AML given induction therapy with 3+7 or more intense standard regimens in UK Medical Research Council/National Cancer Research Institute, Dutch-Belgian Cooperative Trial Group for Hematology/Oncology/Swiss Group for Clinical Cancer Research, US cooperative group SWOG and MD Anderson Cancer Center studies. Age, performance status, white blood cell count, secondary disease, cytogenetic risk and FLT3-ITD/NPM1 mutation status were each independently associated with failure to achieve complete remission despite no early death ('primary refractoriness'). However, the AUC of a bootstrap-corrected multivariable model predicting this outcome was only 0.78, indicating only fair predictive ability. Removal of FLT3-ITD and NPM1 information only slightly decreased the AUC (0.76). Prediction of resistance, defined as primary refractoriness or short relapse-free survival, was even more difficult. Our limited ability to forecast resistance based on routinely available pretreatment covariates provides a rationale for continued randomization between standard and new therapies and supports further examination of genetic and posttreatment data to optimize resistance prediction in AML.

Published
2015
Full Text
View/download PDF

30. Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: Analysis of 1,892 patients from HOVON/SAKK and SWOG

Author

Walter, R.B. (Roland B.), Othus, M. (Megan), Löwenberg, B. (Bob), Ossenkoppele, G.J. (Gert), Petersdorf, S.H. (Stephen H.), Pabst, T. (Thomas), Vekemans, M.-C. (Marie-Christiane), Appelbaum, F.R. (Frederick), Erba, H.P. (Harry P.), Estey, E.H. (Elihu), Walter, R.B. (Roland B.), Othus, M. (Megan), Löwenberg, B. (Bob), Ossenkoppele, G.J. (Gert), Petersdorf, S.H. (Stephen H.), Pabst, T. (Thomas), Vekemans, M.-C. (Marie-Christiane), Appelbaum, F.R. (Frederick), Erba, H.P. (Harry P.), and Estey, E.H. (Elihu)

Published
2015
Full Text
View/download PDF

36. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

Author

Walter, R B, primary, Othus, M, additional, Burnett, A K, additional, Löwenberg, B, additional, Kantarjian, H M, additional, Ossenkoppele, G J, additional, Hills, R K, additional, Ravandi, F, additional, Pabst, T, additional, Evans, A, additional, Pierce, S R, additional, Vekemans, M-C, additional, Appelbaum, F R, additional, and Estey, E H, additional

Published
2014
Full Text
View/download PDF

39. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

Author

Karp, J. E., primary, Garrett-Mayer, E., additional, Estey, E. H., additional, Rudek, M. A., additional, Smith, B. D., additional, Greer, J. M., additional, Drye, D. M., additional, Mackey, K., additional, Dorcy, K. S., additional, Gore, S. D., additional, Levis, M. J., additional, McDevitt, M. A., additional, Carraway, H. E., additional, Pratz, K. W., additional, Gladstone, D. E., additional, Showel, M. M., additional, Othus, M., additional, Doyle, L. A., additional, Wright, J. J., additional, and Pagel, J. M., additional

Published
2012
Full Text
View/download PDF

47. The proportion of CD34+CD38low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia.

Author

Roshal, M, Chien, S, Othus, M, Wood, B L, Fang, M, Appelbaum, F R, Estey, E H, Papayannopoulou, T, and Becker, P S

Subjects
MYELOID leukemia, THERAPEUTICS
Abstract

A letter to the editor in response to the article "The proportion of CD34+CD38low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia" published in a previous 2013 issue is presented.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results